Research Volunteers Needed for New Studies
- Please call our Memory Study Line at 801-587-7888 for more information or to sign up.
- We need volunteers with memory problems as well as healthy volunteers, who may be included in a study's control group.
- If you or someone you care about is interested in helping us learn more about memory problems, our team can answer any questions you may have about clinical research studies or currently available research opportunities.
A Phase III Trial investigating the study drug Solanezumab for Mild to Moderate Alzheimer's Disease in volunteers between the ages of 55-90.
- A Phase III Trial investigating the study drug Gantenerumab for Mild Alzheimer's Disease in volunteers between the ages of 50-90. Trial volunteers will receive study medication for 100 weeks.
- Cognitive Training and Practice Effects in MCI: A study investigating a computerized cognitive training program on improving memory and thinking abilities in volunteers age 65 or older with Mild Cognitive Impairment. Trial volunteers will engage in cognitive training for approximately 13 weeks. For this study, please contact research assistant Bonnie Dalley at (801) 581-3160.
- Implications for the Management of PET Amyloid Technology (IMPACT) NCT02778971:
Click here for more information A study investigating the impact of an amyloid PET scan on physician diagnosis and management, and patient-reported outcomes in early-onset patients not covered by Medicare.
- Imaging Dementia –Evidence for Amyloid Scanning (IDEAS) Study: a Coverage with Evidence Development Longitudinal Cohort: NCT02420756:
Click here for more information
A study investigating the impact of amyloid PET on patient outcomes on Medicare patients (65 years and older).
- Implications for the Management of PET Amyloid Technology in the Imaging Dementia (IDEAS) Trial: NCT02781220:
Click here for more information
A study available to IDEAS participants investigating the impact of an amyloid PET scan on physician diagnosis and management, and patient-reported outcomes.
- Acute Air Quality, Biomarkers, and Cognition in the Elderly: A study investigating the relationship between wintertime inversion air quality and cognition in volunteers age 65 or older with normal cognition or mild cognitive impairment. This study is not currently enrolling new participants.
- A Phase III Trial investigating the study drug Solanezumab for older individuals (ages 65-85) who have normal thinking and memory function but who may be at risk for memory loss due to Alzheimer's disease, but have no outward signs of the disease to participate in the study.
- A Phase III Trial investigating the study drug EVP-6124 for Mild to Moderate Alzheimer's Disease in volunteers between the ages of 55-90. Trial volunteers will receive study medication for 26 weeks.
- A Phase IIa/IIb Trial investigating the study drug MK-7622 as a parallel therapy to Donepezil for Mild to Moderate Alzheimer's Disease in volunteers between the ages of 55-85. Trial volunteers will receive study medication for 33 weeks.
- A Phase II/III Trial investigating the study drug MK-8931 for Mild to Moderate Alzheimer's Disease in volunteers between the ages of 55-85. Trial volunteers will receive study medication for 57 weeks.
- Interested in Learning More About Research?
At the Forefront of Alzheimer's and Dementia Research
One of the Center's major goals is conducting research to better understand the causes of Alzheimer's disease and related memory disorders. Research at CACIR focuses on neuroimaging, clinical trials to examine the effectiveness of new drugs and treatments, and studies that examine the clinical features and pathophysiology of Alzheimer's and related memory disorders.
The Center sets itself apart from other Alzheimer's programs nationwide by implementing its research successes in the Cognitive Disorders Clinic. "We have an opportunity to develop innovative approaches to dementia care," Dr. Foster says. "I am convinced that now is the time to do this." By creating synergy between patient care and clinical research, the Center hopes to improve the standard of dementia care throughout the Intermountain West.
Using advanced imaging techniques and Utah's unique genetics resources, Foster and his colleagues are working to illuminate how specific changes in the brain correlate with differences in patient behavior. They also have shown how neuroimaging can help differentiate between Alzheimer's disease and other causes of dementia, such as frontotemporal dementia — knowledge that can help experts diagnose the cause of dementia more accurately and at earlier stages, when treatments are most effective. To learn more about neuroimaging at CACIR, click here.
To learn more about the University of Utah Alzheimer's Center, and view educational materials such as brochures and posters, please visit our Publications Gallery. To view recent scientific publications by Center faculty members, please click on the links below:
- Gordon J. Chelune, PhD, ABPP: Bio and Publications
- Kevin Duff, PhD, ABPP: Bio and Publications
- Lindsay M. Embree, PhD: Bio and Publications
- Norman L. Foster, MD: Bio and Publications
- R. Brock Frost, PhD: Bio and Publications
- Dustin B. Hammers, PhD, ABPP: Bio and Publications
- Richard D. King, MD, PhD: Bio and Publications